Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mentor has announced that it has taken the first steps toward entry into the US neurological marketplace by completion of enrollment in the Phase I study in its US investigational study of botulinum toxin type A for torticollis or cervical dystonia.
Subscribe to our email newsletter
Joshua Levine, president and CEO of Mentor, said: “We are very excited about the completion of subject enrollment in this clinical trial. We are now planning the next steps in bringing our purified botulinum toxin type A product to this underserved patient population.”